Refametinib (BAY86-9766)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Refametinib (BAY86-9766), covering 2015-04-17 to 2015-04-17. Get the full timeline:
Most recent: Clinical Trial Update: Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer [Phase 1]